Engineering artificial non-coding RNAs for targeted protein degradation

被引:10
作者
Cao, Congcong [1 ]
Li, Aolin [2 ]
Xu, Chaojie [3 ]
Wu, Baorui [4 ]
Yao, Lin [3 ]
Liu, Yuchen [1 ]
机构
[1] Shenzhen Univ, Shenzhen Peoples Hosp 2, Affiliated Hosp 1, Shenzhen Inst Translat Med,Synthet Biol Res Ctr,Hl, Shenzhen, Peoples R China
[2] Shenzhen Univ, Affiliated Hosp 1, Shenzhen Peoples Hosp 2, Dept Urol, Shenzhen, Peoples R China
[3] Peking Univ First Hosp, Dept Urol, Beijing, Peoples R China
[4] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Urol, Div Life Sci & Med, Hefei, Peoples R China
基金
中国国家自然科学基金;
关键词
IN-VITRO; APTAMERS; TRANSCRIPTION; NETWORKS; CATENIN; LNCRNAS;
D O I
10.1038/s41589-024-01719-w
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Targeted protein degradation has become a notable drug development strategy, but its application has been limited by the dependence on protein-based chimeras with restricted genetic manipulation capabilities. The use of long non-coding RNAs (lncRNAs) has emerged as a viable alternative, offering interactions with cellular proteins to modulate pathways and enhance degradation capabilities. Here we introduce a strategy employing artificial lncRNAs (alncRNAs) for precise targeted protein degradation. By integrating RNA aptamers and sequences from the lncRNA HOTAIR, our alncRNAs specifically target and facilitate the ubiquitination and degradation of oncogenic transcription factors and tumor-related proteins, such as c-MYC, NF-kappa B, ETS-1, KRAS and EGFR. These alncRNAs show potential in reducing malignant phenotypes in cells, both in vitro and in vivo, offering advantages in efficiency, adaptability and versatility. This research enhances knowledge of lncRNA-driven protein degradation and presents an effective method for targeted therapies. Cao et al. introduce artificial lncRNA (alncRNA) for targeted protein degradation by engineering and linking lncRNA HOTAIR sequence to RNA aptamers. The resulting alncRNAs degrade oncogenic proteins, such as c-MYC and KRAS, showing promise for cancer therapies.
引用
收藏
页码:393 / 401
页数:24
相关论文
共 50 条
[1]   LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation [J].
Ahn, Green ;
Banik, Steven M. ;
Miller, Caitlyn L. ;
Riley, Nicholas M. ;
Cochran, Jennifer R. ;
Bertozzi, Carolyn R. .
NATURE CHEMICAL BIOLOGY, 2021, 17 (09) :937-946
[2]   Long Noncoding RNAs: Cellular Address Codes in Development and Disease [J].
Batista, Pedro J. ;
Chang, Howard Y. .
CELL, 2013, 152 (06) :1298-1307
[3]   Regulation of Nrf2 and NF-κB activities may contribute to the anti-inflammatory mechanism of xylopic acid [J].
Boakye, Yaw Duah ;
Osafo, Newman ;
Oppong-Kyekyeku, James ;
Abotsi, Wonder Kofi Mensah ;
Boakye-Gyasi, Eric ;
Heiss, Elke ;
Agyare, Christian .
INFLAMMOPHARMACOLOGY, 2022, 30 (05) :1835-1841
[4]   Targeting transcription factors in cancer - from undruggable to reality [J].
Bushweller, John H. .
NATURE REVIEWS CANCER, 2019, 19 (11) :611-624
[5]   Covalent Triazine Framework as Catalytic Support for Liquid Phase Reaction [J].
Chan-Thaw, Carine E. ;
Villa, Alberto ;
Katekomol, Phisan ;
Su, Dangsheng ;
Thomas, Arne ;
Prati, Laura .
NANO LETTERS, 2010, 10 (02) :537-541
[6]   Inducible Degradation of Oncogenic Nucleolin Using an Aptamer-Based PROTAC [J].
Chen, Miao ;
Zhou, Ping ;
Kong, Yun ;
Li, Jingrui ;
Li, Yan ;
Zhang, Yao ;
Ran, Jie ;
Zhou, Jun ;
Chen, Yan ;
Xie, Songbo .
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (02) :1339-1348
[7]   Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1 [J].
Cotton, Adam D. ;
Nguyen, Duy P. ;
Gramespacher, Josef A. ;
Seiple, Ian B. ;
Wells, James A. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2021, 143 (02) :593-598
[8]   Reprogramming Cellular Behavior with RNA Controllers Responsive to Endogenous Proteins [J].
Culler, Stephanie J. ;
Hoff, Kevin G. ;
Smolke, Christina D. .
SCIENCE, 2010, 330 (6008) :1251-1255
[9]   Drugging the 'undruggable' cancer targets [J].
Dang, Chi V. ;
Reddy, E. Premkumar ;
Shokat, Kevan M. ;
Soucek, Laura .
NATURE REVIEWS CANCER, 2017, 17 (08) :502-508
[10]   MYC as a target for cancer treatment [J].
Duffy, Michael J. ;
O'Grady, Shane ;
Tang, Minhong ;
Crown, John .
CANCER TREATMENT REVIEWS, 2021, 94